Accelerated Radiotherapy Outcomes in Women

Ontario Clinical Oncology Group (OCOG)1,234 enrolled

Overview

This study is evaluating the long-term outcomes of women in a randomized trial that compared accelerated whole breast irradiation (42.5 Gy in 16 fractions over 22 days) to a longer conventional schedule of whole breast irradiation (50 Gy in 25 fractions over 35 days) following breast-conserving surgery. The results reported at 5 years demonstrated equivalence for these two different radiation schedules for the effect of local recurrence in the breast and cosmetic outcome. Emerging data has suggested that accelerated or shorter radiation schedules may potentially be associated with an increased risk of late morbidity of the skin, soft tissue and the heart at 10 years and beyond. The purpose of this study is to evaluate the long term outcomes of women randomized in the trial. The outcomes evaluated will include cosmetic outcome and cardiac disease as a measure of late radiation morbidity and local breast recurrence as a measure of effectiveness.

Study Type

OBSERVATIONAL

Enrollment

1,234

Conditions

Breast Cancer

Interventions

Conventional radiotherapy scheduleRADIATION

50 Gy in 25 fractions over 35 days

Accelarated radiotherapy scheduleRADIATION

42.5 Gy in 16 fractions over 22 days

Eligibility

Sex: FEMALE

Medical Language ↔ Plain English

Only patients recruited into the "Randomized Trial of Hypofractionated Radiotherapy Post-Lumpectomy in Women with Node Negative Breast Cancer" study are eligible to be enrolled into this study. Inclusion Criteria: 1. The female patient has a histological diagnosis of invasive carcinoma of the breast, and no evidence of metastatic disease. 2. Has had a lumpectomy (including segmental resection and partial mastectomy), that is, surgical excision of the tumour with a rim of normal tissue. 3. Patient has not had an axillary dissection, OR for patients who have had an axillary dissection, all nodes are negative for metastatic disease. Exclusion Criteria: 1. Tumour greater than 5 cm in greatest diameter on pathological examination. 2. The presence of invasive or intraductal (noninvasive) breast cancer involving the surgical margins. 3. Clinical evidence prior to surgery of infiltration of the skin of the involved breast such as edema, ulceration, or fixation of the tumour to underlying muscle, or inflammatory breast cancer. 4. Bilateral malignancy of the breast (synchronous or metachronous). 5. More than one primary invasive tumour in the same breast. 6. Previous surgery for breast cancer. 7. Pathological status of axilla is unknown. 8. Status for adjuvant systemic therapy not determined. 9. For patients not treated with adjuvant chemotherapy: unable to commence radiation therapy within 16 weeks of last surgical procedure on the breast. 10. For patients treated with adjuvant chemotherapy: unable to commence radiation therapy within 8 weeks of the last dose of chemotherapy. 11. Serious nonmalignant disease (eg. cardiovascular, renal, etc.) which would preclude surgical or radiation treatment. 12. Currently pregnant or lactating. 13. Breast deemed too large to permit satisfactory radiation (ie. separation \> 25 cm). 14. Previous concomitant malignancies of any type except squamous, or basal cell carcinomas of the skin, or carcinoma in situ of the cervix which have been effectively treated. 15. Geographic inaccessibility for follow-up. 16. Psychiatric or addictive disorders which preclude obtaining informed consent or adherence to the protocol.

Locations (11)

Regional Cancer Program of the Sudbury Regional Hospital

Greater Sudbury, Ontario, Canada

Juravinski Cancer Centre

Hamilton, Ontario, Canada

Cancer Centre of Southeastern Ontario at Kingston General Hospital

Kingston, Ontario, Canada

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.